Facile Accelerated Specific Therapeutic (FAST) Platform to Counter Multidrug-Resistant Bacteria

Kristen A. Eller^{1,#}, Thomas R. Aunins^{1,#}, Colleen M. Courtney^{1,5}, Jocelyn K. Campos¹,
Peter B. Otoupal^{1,6,7}, Keesha E. Erickson^{1,4}, Nancy E. Madinger², and Anushree
Chatterjee^{1,3*}

¹Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO
80303

²Division of Infectious Diseases, University of Colorado Denver, Aurora, CO 80045

³Biomedical Engineering, University of Colorado Boulder, Boulder, CO 80303

Current affiliations:

⁴Theoretical Biology & Biophysics Group, Theoretical Division, Los Alamos National
Laboratory, Los Alamos, NM 87545

⁵Biotechnology & Bioengineering Department, Sandia National Laboratories, P.O. Box
969, Livermore, CA 94550

⁶Joint Bioenergy Institute, 5885 Hollis St. Emeryville, California 94608

⁷Joint Bioenergy Institute Biomass Science and Conversion Technologies, Sandia
National Laboratories, P.O. Box 969, Livermore, CA 94550

These authors contributed equally

*Corresponding Author: Email: chatterjee@colorado.edu

ABSTRACT

Multidrug-resistant (MDR) bacteria pose a grave concern to global health. This problem is further aggravated by a lack of new and effective antibiotics and countermeasure platforms that can sustain the creation of novel antimicrobials in the wake of new outbreaks or evolution of resistance to antibiotics. To address this, we have developed a Facile Accelerated Specific Therapeutic (FAST) platform that can develop effective therapies against MDR bacteria within a week. Our FAST platform combines four essential modules- design, build, test, and delivery- of drug development cycle. The design module comprises a bioinformatics toolbox that predicts sequence-specific peptide nucleic acids (PNAs) that target non-traditional pathways and genes of bacteria in minutes. The build module constitutes in-situ synthesis and validation of selected PNAs in less than four days and efficacy testing within a day. As a proof of concept, these PNAs were tested against MDR clinical isolates. Here we tested Enterobacteriaceae including carbapenem-resistant *Escherichia coli*, extended-spectrum beta-lactamase (ESBL) *Klebsiella pneumoniae*, New Delhi Metallo-beta-lactamase-1 carrying *Klebsiella pneumoniae* and MDR *Salmonella enterica*. PNAs showed significant growth inhibition for 82% of treatments, with nearly 18% of the treatments leading to more than 97% decrease. Further, these PNAs are capable of potentiating antibiotic activity in the clinical isolates despite presence of cognate resistance genes. Finally, FAST offers a novel delivery approach to overcome limited transport of PNAs into mammalian cells to clear intracellular infections. This method relies on repurposing the bacterial Type III secretion system in conjunction with a kill switch that is effective at eliminating 99.6% of an intracellular *Salmonella* infection in human epithelial cells. Our findings demonstrate the potential of the FAST platform in treating MDR bacteria in a rapid and effective manner.

Keywords: Multi-drug resistant bacteria, Peptide nucleic acids, rationally designed therapy, Type III secretion system.

The development of antibiotic resistance is an emerging crisis in worldwide public health^{1–4} and is outpacing the pipeline of new small molecule drugs^{5–7}. The large majority of drugs in clinical development for priority pathogens—as defined by the World Health Organization²—do not introduce new classes or targets and are not pathogen-specific⁵, thus presenting higher risk of rapid bacterial adaptation^{1,8–12}. Due to rapid, pervasive bacterial adaption there is a need for countermeasure platforms that can generate antimicrobial solutions in a facile and accelerated manner. Antisense therapeutics offer the potential for gene sequence-specific therapies that can target a broader range of pathways in bacteria, are faster to design, and are more adaptive to resistance than conventional small molecule antibiotics^{13,14}. Peptide nucleic acids (PNA) present an antisense strategy that offer advantages in stability^{15,16}, binding strength¹⁷, and mismatch discrimination compared to similar technologies¹⁸. Prior research from our lab and others have demonstrated the utility of PNA as an antibiotic platform^{19–24}.

Despite these advantages, previous PNA work has relied on tedious design and screening processes to maximize stability and specificity of PNAs^{20,25,26}. Additionally, the inefficient transport of PNA across cell membranes, as well as the lack of a systematic effort to target non-traditional antibiotic pathways, has limited the development of PNA as useful antibiotics. We address these limitations through the introduction of Facile Accelerated Specific Therapeutics (FAST), a semi-automated platform for the quick and efficient design, synthesis, testing, and delivery of PNA antisense antibiotics (Fig. 1). We are able to complete this full process in under five days. The FAST platform uses the PNA Finder toolbox to design PNA candidate sequences in less than 10 minutes, which we then synthesized, purified, and tested in parallel on a panel of multidrug-resistant (MDR) clinical isolates to validate the toolbox's predictions. These results can then be recycled to the PNA Finder toolbox to improve upon specificity predictions. Finally, promising PNAs are delivered to treat intracellular infections of bacteria.

The PNA Finder bioinformatics toolbox offers the functions *Get Sequences* and *Find Off-Targets*, which comprise automated workflows that combine custom Python 2.7 scripts with the alignment and analysis programs Bowtie 2²⁷, SAMTools²⁸, and BEDTools²⁹. *Get Sequences* is used to create a library of PNA candidate sequences that

target the mRNA translation start codons of a user-defined set of genes. The function takes a list of gene IDs and searches a genome annotation file for matches, which can then be used to extract nucleotide sequences from a corresponding genome assembly. Additionally, *Get Sequences* provides sequence warnings for PNA solubility and self-complementarity issues, as well as a protein interaction network analysis via the STRING database³⁰. The PNA sequences provided by *Get Sequences* are used as inputs for the *Find Off-Targets* function, which searches for incidental inhibitory alignments by searching a non-target genome for highly similar sequences—1-bp mismatch or less—within a 20 nucleotide range of the start codon²⁶. This function allows for the design of highly specific PNAs that target only the desired gene in the specific pathogens of interest, while avoiding broad inhibitory action against other pathogens, the human microbiome, and the human transcriptome.

In this study we applied the FAST platform to the creation of PNA antibiotics for clinical isolates of five MDR Enterobacteriaceae isolates: two *Escherichia coli* isolates, two *Klebsiella pneumoniae* isolates, and one *Salmonella enterica* serovar Typhimurium isolate. To design the set of candidate sequences, the *Get Sequences* tool was used with a list of 296 essential and 4,090 non-essential *E. coli* genes, as well as the genome assembly and annotations for reference strain *E. coli* MG1655 (Fig. 2A). The *Find Off-Targets* tool was used with this list to find off-targets within the *E. coli* genome, in order to avoid inhibition of unintended genes that could confound results. After filtering all PNA with 0-bp mismatch off-targets we were left with a library of 260 PNA candidates targeting essential genes and 3,524 candidates targeting non-essential genes within *E. coli*. We ran this list of candidates through *Find Off-Targets* twice: first with *K. pneumoniae* (KPN) reference genome MGH 78578, then *Salmonella enterica* serovar Typhimurium (STm) reference genome SL1344. The alignments of PNA candidates to these genomes were analyzed to determine which would be predicted to target *K. pneumoniae* and *S. Typhimurium* genes that are analogous to the original *E. coli* gene target. From this analysis we identified 101 essential and 278 non-essential PNA candidates that showed target sequence homology between the three reference genomes. Finally, we eliminated PNAs that were predicted by the *Get Sequences* tool to have low solubility or exhibit self-

complementarity, resulting in a list of 71 essential and 243 non-essential target gene candidates. The duration of this computational design pipeline was under ten minutes.

For testing with the MDR isolates, we first selected two novel gene targets with functions related to those inhibited by conventional antibiotics: *gyrB*³¹ (protein gyrase subunit B) and *rpsD*³² (30S ribosomal protein S4) (Fig. 2A). These genes contribute to pathways similar to those inhibited by fluoroquinolones and tetracycline/aminoglycosides respectively. We then chose three non-conventional antibiotic gene targets: *ffh*³³ (signal recognition particle protein, essential), *lexA*³⁴ (SOS response repressor protein, essential), and *acrA*³⁵ (transmembrane transport protein, non-essential). We also selected PNA targets that were not from the 71 essential or 243 non-essential candidates with homology in all three MDR species to demonstrate the PNA's species selectivity. We selected one essential and two non-essential targets in non-traditional pathways specific to only *E. coli*: *folC*³⁶ (essential, H2 folate synthetase), *csgD*³⁷ (curli fimbriae expression, non-essential), and *fnr*³⁸ (anaerobic metabolism, non-essential). Additionally, we chose to target *recA*³⁹ (SOS double stranded break repair, non-essential) because it shows homology to *E. coli* and Salmonella but not KPN.

The efficiency of the PNA Finder tool reduces the requisite time to obtain antisense antibiotic sequences, and the discovery period becomes limited merely by the duration of the FAST platform's synthesis, purification, and testing. Prior to testing on MDR clinical isolates, we selected two of this set of PNA, α -rpsD and α -lexA, to evaluate how quickly these latter steps of the FAST pipeline could be accomplished. It was determined that solid-phase synthesis, using Fmoc chemistry at a 10-micromole scale, of the 23-residue peptides (see Methods, Supplemental S1) required less than three days. This was followed by purification using High Performance Liquid Chromatography (HPLC), confirmation using Liquid chromatography–mass spectrometry (LC-MS), and lyophilization; this process required less than seven hours (Fig. 2B). Testing required an additional 24-hour experiment and validated the predicted toxicity of PNA against their essential gene targets in *E. coli* reference strain MG1655 (Fig. S2 & S3).

Prior to treatment of MDR clinical isolates with the PNA designed by the FAST platform, we characterized both the phenotypic and genotypic resistance profiles of the five MDR clinical isolates that were obtained. These isolates included a carbapenem-resistant Enterobacteriaceae (CRE) *E. coli*, an MDR *E. coli*, an extended spectrum β -lactamase (ESBL)-producing *K. pneumoniae* (KPN), a New Delhi Metallo β -lactamase 1 (NDM-1) KPN, and an MDR *S. enterica* serovar Typhimurium (STm). Phenotypic antibiotic resistance characterization of the clinical isolates was performed using nine antibiotics of varied mechanisms and classes, and comparing to 2016-2017 CLSI breakpoint values⁴⁰ (Fig. 2C, Table S1). We found all isolates to have resistance to two or more antibiotics, with CRE *E. coli* showing resistance to all nine antibiotics tested. Genome sequencing showed all of the clinical isolates to have at least two unique antibiotic resistance genes, and at least one β -lactamase gene (Fig. 2C, Table S2). The sequencing also allowed us to confirm the presence of each antisense target sequence in each isolate. Additionally, *Find Off-Targets* was used to search these genome assemblies for off-targets around the start codon. Among all PNA and MDR strains we predicted only one PNA to have a single inhibitory off-target in each clinical isolate, α -rpsD in MDR STm and α -acrA in CRE *E. coli*, MDR *E. coli*, ESBL KPN, and NDM-1 KPN (Fig. S4, Table S3).

Each PNA was conjugated to the cell-penetrating peptide (CPP) (KFF)₃K to enhance transmembrane transport^{22,23,41,42} and administered to clinical isolates at a 10 μ M concentration, based on the minimum inhibitory concentration (MIC) observed in *E. coli* MG1655, to assess the toxicity of each as a monotherapy (Fig. S3). Inhibition was compared to a scrambled sequence PNA (α -nonsense) as a control. Eighteen out of 34 treatments that showed homology to target clinical isolates demonstrated at least 50% growth inhibition, as shown in Fig. 2D-F. The PNA α -rpsD was found to be the most successful monotherapy, causing a greater than 50% growth reduction in all five clinical isolates (Fig. 2D&E, Fig. S5). α -gyrB, α -lexA, and α -ffh were found to significantly inhibit growth in all clinical isolates but NDM-1 KPN (p-val < 0.05). Of the PNAs targeted to only *E. coli*, α -folC (Fig. 2E), and α -csgD (Fig. 2F), successfully inhibited growth (p-val < 0.05) in both *E. coli* isolates, whereas α -fmr (Fig. S5) was effective against only the CRE *E. coli* strain. α -recA, which is specific to STm and *E. coli*, was effective against both *E. coli*

strains and MDR STm. PNA treatments demonstrated high selectivity to their target strains. Of the 45 total treatments, 34 were predicted to have homology to the clinical isolate tested and eleven did not. Seven out of eleven PNA treatments without sequence homology to the clinical isolate showed no growth reduction; the remaining four showed less than 10% growth inhibition (Fig. S5). Of the 34 clinical isolate-PNA pairs predicated to have homology 28 showed significant growth inhibition, with 6 monotherapy treatments reducing growth by more than 97% (Fig. 2F, Fig. S5). This success rate is remarkable given the high difficulty in treating these strains with conventional antibiotic strategies.

In analyzing these results, we looked for correlations between growth inhibition and each gene target's corresponding mRNA abundance level, secondary structure, and protein network interactions (Fig. S6, S7). Though a trend has been suggested in previous antisense antibiotic research⁴³, we did not identify any correlation between predicted secondary structure and growth inhibition; nor did we identify a correlation with mRNA abundance. We observed a significant correlation (Pearson correlation coefficient $r=0.908$, $p\text{-val}<0.001$) between growth inhibition and protein interaction network connectedness denoted by average node degree—as identified by STRING protein network analysis³⁰ (Fig. 3A). The positive correlation indicates that the more interconnected a network is the more susceptible it is to PNA treatment. Conversely, loosely connected protein interaction networks (low node degree) showed weaker monotherapy effects.

We tested PNAs that showed minimal to moderate growth inhibition in monotherapy treatment in combination with small molecule antibiotics to which the MDR clinical isolates had demonstrated resistance (Fig. 2C, Fig 3B-M). Treatment interaction was evaluated using the Bliss Independence model⁴⁴, with positive S-values indicating synergy or greater inhibition than predicted by a simple additive effect. In CRE *E. coli* we identified significant synergistic interaction between α -gyrB (10 μ M, essential), and both chloramphenicol (8 μ g/mL, Fig. 3B&D, Fig. S8) and gentamicin (4 μ g/mL, Fig. 3E, Fig. S8) with s-values of 0.64 ± 0.09 and 0.56 ± 0.12 , respectively. Additionally, the nonessential PNA targets of α -acra, α -csgD, and α -recA all showed significant synergistic interaction with gentamicin (4 μ g/mL, 10 μ M PNA, Fig. 3F-I, Fig. S8). The CRE *E. coli*

isolate possesses resistance genes specific to the mechanisms of each antibiotic (Fig. 2C, Table S2), yet it was still possible to re-sensitize it to the antibiotics at their CLSI breakpoints (Table S1). We also identified significant synergistic interaction in ESBL KPN between the PNAs α -ffh, α -lexA, and α -gyrB (10 μ M) and tetracycline (2 μ g/mL, Fig. 3J-M, Fig. S8). Our data showed a negative correlation ($r = -0.3017$, $p\text{-val} < 0.05$, Fig. 3N) between the degree of synergy and average node degree, indicating that targeting genes that have less interconnected protein interaction networks could give rise to synergy with antibiotics. Further, in contrast with previous research that showed a higher degree of antibiotic synergy between antisense oligonucleotides and small molecule drugs when the treatments targeted related pathways^{45,46}, our results indicate that unrelated mechanisms of inhibition can also result in combination effects in MDR pathogens. Our data demonstrate that the FAST platform is capable of designing PNAs that can be highly effective both as a monotherapy as well as potentiators of traditional antibiotics in drug-resistant pathogens. Further, FAST provides insights into the role protein interaction networks have in PNA's therapeutic activity and provides an approach to expand both the utility of the platform and the effective supply of usable antibiotics against MDR pathogens.

The final obstacle for PNA antibiotic viability that the FAST platform seeks to address is the molecules' poor uptake into mammalian cells to treat mammalian intracellular infections^{47,48}. Though conjugation to a CPP improves PNA transmembrane transport in bacteria, transport into mammalian cells still remains limited, creating challenges for *in vivo* application of the therapy. Though nanoparticle and lipoparticle based approaches are being developed, these have challenges of poor tissue targeting and lower stability⁴⁷. To overcome some of these limitations, here we present a probiotic-based delivery approach for delivering antisense oligomers to infected mammalian cells. In the delivery phase of the FAST platform, we present a first probiotic prototype for PNA transport using the Type III secretion system (T3SS), a gram-negative bacterial machine for invasion of the eukaryotic host cell^{49,50}, combined with a lysis switch to release the therapeutic.

First, we sought to establish that a strain expressing the T3SS was capable of transporting PNA— α -rpsD and α -lexA were chosen for this evaluation—into human epithelial cells (HeLa). We confirmed that PNAs are not lethal to mammalian cells in the range tested (Fig. S9). To confirm transport into mammalian cells we used the *S. Typhimurium* strain SL1344, which expresses both the T3SS and green fluorescent protein (GFP)⁵¹ (the strain is referred to from here as STm-GFP). We examined transport effectiveness of PNA delivered into HeLa cells via the bacteria's T3SS-mediated infection (T3SS-PNA conditions) compared to PNA added extracellularly post T3SS infection (naked PNA conditions) by measuring intracellular STm-GFP clearance (Fig 4A). For both conditions HeLa cells were infected with STm-GFP at a multiplicity of infection (MOI) of 10 for 45 minutes. For the T3SS-PNA conditions STm-GFP were exposed to 10 μ M α -rpsD or α -lexA PNA during the 45-minute infection. Within this time the PNA was allowed to enter the STm-GFP as it infected the HeLa cells, but this time period was not long enough for PNA to decrease STm-GFP viability (Fig. S10). After 45 minutes of infection, the cells of both conditions (T3SS-PNA and naked PNA) were washed and incubated in gentamicin-containing media to remove remaining extracellular bacteria then incubated for a period of 18 hours. For the naked-PNA treatment PNA was only added during this 18-hour incubation period. Both α -rpsD and α -lexA inhibited STm-GFP intracellular growth by more than 60% in the T3SS-PNA conditions (Fig 4B&C, Fig. S11), whereas neither reduced infection in the naked PNA condition even though PNA was added extracellularly for 18 hours as compared to the 45-minute co-incubation. The same experiment was repeated in a different mammalian cell line, murine osteoblasts, with reproducible results indicating it is not a unique phenomenon to a HeLa intracellular infection (Fig. S12). These results demonstrate that *S. Typhimurium*, expressing the T3SS, can act as a delivery vessel of PNA into human epithelial cells.

We next engineered the STm-GFP strain to release PNA into the mammalian cell to target a separate intracellular pathogen. We constructed a modified strain of STm-GFP in which cell lysis can be induced by a holin-endolysin system⁵² under the control of a *laciQ* promoter (strain referred to as Delivery STm, Fig. S13) to treat a separate intracellular pathogen, SL1344 expressing mCherry via a plasmid (strain referred to as Target STm). This promoter had a lac operator downstream, which has been shown to

1 permit RNA polymerase readthrough even for tightly bound LacI proteins⁵³, which
2 enabled basal expression sufficient to cause Holin-induced lysis in the absence of IPTG
3 induction (Fig. S16, S13B). To demonstrate assay generalizability, we used a different
4 PNA, α -recA, which was found to be lethal to STm-GFP at 10 μ M (Fig. S14). To treat a
5 separate intracellular infection, we allowed a 45-minute incubation period of the Delivery
6 STm—with either 10 μ M α -recA (T3SS/Holin-PNA condition) or PBS (no treatment). The
7 Target STm was incubated with PBS in parallel at equal cell densities. Delivery STm (with
8 or without PNA) was washed to remove any extracellular PNA and was then co-incubated
9 with the Target STm and HeLa cells, at a 4:1 ratio of Delivery to Target STm to achieve
10 a combined MOI of 10. The cultures were then washed again and incubated in
11 gentamicin-containing media for 18 hours to remove extracellular bacteria (Fig. 4D).
12 Growth inhibition was measured by comparing the ratio of bacterial load after to before
13 infection, to account for any variability in initial bacterial load used for infection across
14 replicates. In the T3SS/Holin-PNA condition the intracellular load of the Target STm,
15 normalized to the Delivery STm load, was reduced by more than 99% compared to the
16 no PNA treatment condition. For two out of three biological replicates, the target strain
17 was completely eliminated across a range of MOI (Fig. 4E, Fig. S15 & 16). In contrast,
18 when using a non-T3SS bacteria, *E. coli* MG1655, as the delivery strain, there was no
19 decrease in the Target STm load (Fig. 4F). These data provide evidence that a
20 combination of the T3SS with a holin-endolysin system is an effective solution for the
21 delivery of PNA to treat intracellular infections, which remains a major hurdle in antisense
22 antibiotic treatments. Though *S. Typhimurium* is a pathogenic species, future work
23 towards the expression of the T3SS and holin-endolysin system within a probiotic species
24 will enable the efficient and safe transport of PNA into mammalian cells.

25 We have demonstrated the utility of the FAST platform to quickly and effectively
26 create PNA antibiotics, through the stages of design, synthesis, testing, and delivery.
27 Development of the FAST platform will help to create a much needed rapid and adaptive
28 countermeasure platform for accelerating the response to emergence of multidrug
29 resistance. The PNA Finder toolbox is capable of designing and screening hundreds of
30 PNA candidates simultaneously, in order to narrow down a list of sequences that
31 specifically target a harmful pathogen while avoiding targeting other species. The quick

design process allows for the creation and testing of potential antibiotic therapies in under a week, and our results have demonstrated that this rational design process results in much higher monotherapy success rates than conventional small molecule screening pipelines⁵⁴. Additionally, we demonstrate the utility of the FAST platform to create antibiotics that are effective potentiators of conventional antibiotic activity, even in strains with specifically identified to have resistance to small molecule drugs. Finally, we have engineered a hybrid type III secretion/holin-endolysin system for effective therapeutic intracellular delivery. The results presented can help develop a novel probiotic PNA delivery method and improve FAST platform's relevance for clinical applications. The application of the FAST platform to design of pathogen- and gene-specific antibiotics in non-traditional antibiotic pathways could be instrumental in the development of new antibiotics for already pervasive MDR pathogens.

Acknowledgments: We acknowledge financial support from W. M. Keck Foundation. and DARPA Young Faculty Award (D17AP00024) and National Aeronautics and Space Administration (NASA) Cooperative Agreement Notice – Translational Research Institute (TRISH) award number NNX16A069A to A.C., NSF Graduate fellowship (DGE 1144083) to C.M.C. We thank RY Young from Texas A&M University for gifting the pRG1 plasmid. We thank Ryan Felton and Teruna J. Siahaan from The University of Kansas for the synthesis of PNA for toxicity studies in HeLa (Fig.S9). The views, opinions, and findings contained in this article are those of the author and/or should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the Department of Defense. All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data available from authors upon request.

Author Contributions: K.A.E., C.M.C., T.R.A., and J.K.C., conducted all experiments. N.E.M. provided the clinical isolates. K.E.E and T.A. performed the de novo assembly and sequence analysis for the clinical isolates. T.A. performed PNA synthesis and bioinformatics analysis and PNA off-target search across bacterial genomes. P.B.O. performed the protein interaction network analysis. A.C., C.M.C., K.A.E., and J.K.C., analyzed the experimental data. K.A.E., J.K.C., C.M.C., and A.C. analyzed HeLa infection data. A.C., C.M.C., K.A.E., P.B.O., and T.A. wrote the paper. All the authors discussed the results and edited the manuscript.

Competing Financial Interests: The authors (A.C., and C.M.C.), (A.C., K.A.E., and J.K.C.), and (A.C. and T.A.) have filed patents on this technology.

Materials and Methods

PNA Finder toolbox: The PNA Finder toolbox is built using Python 3.7, as well as the alignment program Bowtie 2 (version 2.3.5.1)²⁷, the read alignment processing program SAMtools (1.9)²⁸, and the feature analysis program BEDTools (v2.25.0)²⁹. Additionally, in order to run on a Windows operating system, the toolbox requires a Window-compatible bash shell (the program Cygwin has been used in development) to provide a Unix-like environment in which Bowtie 2, SAMtools, and BEDTools can be compiled and run. Mac operating systems are not currently supported by the toolbox. The user interface for the PNA Finder Toolbox is constructed using the Python 3.7 package Tkinter, version 8.6.

Gene target selection: Essential genes were identified using the Keio collection entry in the Database of Essential Genes (DEG⁵⁵). PNA sequences were identified using lists of gene IDs from DEG as inputs for the custom Python script, which uses a genome annotation and associated assembly to extract the reverse complements of 12-mer nucleotide sequences centered on the mRNA AUG start codons (STC) for the genes of interest. Using the *Find Off-Targets* function of the PNA Finder toolbox, these sequences were screened for off-target alignments within the genome assembly for *E. coli* MG1655 (RefSeq: GCF_000005845.2), from which the PNA sequences originated, as well as for targeting homology within the genome assemblies for KPN MGH 78578 (RefSeq: GCF_000016305.1) and STm SL1344 (RefSeq assembly: GCF_000210855.2). PNA-RNA complements were predicted to cause inhibition if they were located within 20 bases of the mRNA start codon, based on previous work²⁶. The *Get Sequences* function of the PNA Finder toolbox was used to search for indicators of low solubility as described by Gildea et al⁵⁶, such as purine stretches greater than 5 bases, a purine content of greater than 50%, or a guanine-peptide stretch of longer than 3 bases. The function also searched for self-complementary sequences of greater than 5 bases. PNA target pathways were identified using EcoCyc⁵⁷ and Regulon Database⁵⁸.

PNA Synthesis: All PNAs contained sequences complementary to target mRNA, as well as the CPP (KFF)₃K attached via an AEEA or O linker. These sequences are provided in Fig. S1. PNA for the toxicity studies (Fig. 2B, growth curve, & Fig. S8 α -nonsense in first row) were synthesized using an Apex 396 peptide synthesizer (AAPPTec, LLC) to

perform solid-state PNA synthesis using Fmoc chemistry on MBHA rink amide resin at a 10 μ mol scale. Fmoc-PNA monomers were obtained from PolyOrg Inc. A, C, and G monomers are protected at amines with Bhoc groups. All PNAs were synthesized with a CPP (KFF)₃K, which has lysine residues protected with Boc groups. PNA products were precipitated and purified as trifluoroacetic acid salts. PNAs used in MDR clinical isolate growth experiments were ordered from PNA Bio Inc. (Newbury Park, CA), and were also conjugated to the cell-penetrating peptide (KFF)₃K. PNA used for the toxicity measurements in mammalian cells was a generous gift provided Prof. Teruna Siahaan's lab (Fig. S9). PNA was dissolved in H₂O with 5% DMSO at 100 μ M. Stocks were stored at -20°C for long-term and at 4°C for working stocks to minimize freeze/thaw cycles.

Bacterial cell culture: The clinical isolates were obtained from the lab of Nancy Madinger at the University of Colorado Anschutz campus. Clinical isolates were grown in Cation Adjusted Mueller Hinton broth (CAMHB) (Becton, Dickinson and Company 212322) at 37°C with 225 rpm shaking or on solid CAMHB with 1.5% agar at 37°C. Clinical isolates were maintained as freezer stocks in 90% CAMHB, 40% glycerol at -80°C. Freezer stocks were streaked out onto solid CAMHB and incubated for 16 h to produce single colonies prior to experiments. For each biological replicate, a single colony was picked from solid media and grown for 16 h in liquid CAMHB prior to experiments. Non-clinical isolates, such as *E. coli* MG1655 (ATCC700926) and *Salmonella enterica* serovar Typhimurium SL1344, were cultured in liquid 2% lysogeny broth (LB) or on 2% LB with 1.5% agar for solid plates. SL1344 cultures were supplemented with 30 μ g/mL streptomycin and SL1344 strains containing plasmids pFPV (Target STm) or pRG1 modified with a lacIq promotor (SL1344-Holin) were supplemented with 100 μ g/mL ampicillin. Freezer stocks were stored in 60% LB broth, 40% glycerol at -80°C. Freezer stocks were streaked out onto solid LB and incubated for 16 h to produce single colonies before experiments. For biological replicates, single colonies were started in liquid LB and grown for 16 hours prior to experiments. *E. coli* MG1655 PNA growth experiments were carried out in M9 media (1x M9 minimal media salts solution (MP Biomedicals), 2.0 mM MgSO₄, and 0.1 mM CaCl₂ in sterile water) with 0.4% glucose.

Antibiotic resistance screening: Sensitive/resistant breakpoints were taken from the 2016-2017 Clinical & Laboratory Standards Institute report⁴⁰ (Table S1). Liquid cultures of the clinical strains were diluted to a 0.5 McFarland standard and added to the respective antibiotic test condition. The antibiotic minimum inhibitory concentration (MIC) for each clinical isolate was determined as the lowest antibiotic concentration which prevented visible cell growth for 24 h. Strains were: “sensitive” if the MIC was equal to or below the sensitive-breakpoint concentration, “resistant” if the MIC was greater than or equal to the resistant-breakpoint concentration, and “intermediate” if the MIC was in-between.

Genome sequencing library prep and data analysis: Liquid cultures were inoculated from individual colonies off of solid cation-adjusted Mueller-Hinton broth (CAMHB) for each clinical isolate. Cultures were grown for 16 h as described above and then 1 mL of culture was used to isolate DNA using the Wizard DNA Purification Kit (Promega). A Nanodrop 2000 (Thermo Scientific) was used to measure DNA concentration and purity. For library preparation, >2 µg of DNA was submitted in 50-100 µL samples. The libraries were prepared for sequencing using Nextera XT DNA Library Preparation Kit (Illumina), and the sequencing was run with a 2x250 bp MiSeq run (Illumina).

Sequencing reads were first trimmed using TRIMMOMATIC v0.32⁵⁹ for length and quality with a sliding window. For further analysis, the trimmed files, of only paired sequences, were transferred to Illumina BaseSpace (<http://basespace.illumina.com>). We assessed the sequencing quality using FASTQC v1.0.0 and performed de novo genome assembly with SPAdes Genome Assembler v3.6.0^{60,61}. The assembly was further corrected and improved using Rescaf v 1.0.1, and then we performed annotation using PROKKA v1.0.0⁶². Antibiotic resistance genes were identified and characterized using SEAR and ARG-ANNOT pipelines^{63,64}. Integrated Genomics Viewer⁶⁵ was used for data visualization.

Homology analysis for PNA in clinical isolates: The PNA Finder *Find Off-Targets* function was used to identify homologous nucleotide sequences and determine whether PNA complementation at these loci would be predicted to cause translation inhibition. For *S. Typhimurium* and *K. pneumoniae* strains, annotations were examined manually to

determine whether the PNA would be expected to inhibit a gene analogous to its original *E. coli* target.

PNA growth assay: Biological replicates were diluted 1:10,000 into treatment condition in 384-well plates and measured for 24 h in a Tecan GENios at 562 nm with a bandwidth of 35 nm. Media absorbance blanks were subtracted from data prior to analysis. Normalized optical density (OD) data is shown normalized to the “no treatment” growth curves at 16 hours.

Potentiation of antibiotics with PNAs: Combination growth curve experiments were performed following the same procedure as the PNA growth assay mentioned above, except for the addition of antibiotics tetracycline (2 µg/mL), gentamicin (4 µg/mL), chloramphenicol (8 µg/mL), and meropenem (8 µg/mL) where appropriate.

Combinatorial effects were evaluated using the Bliss Independence model⁶⁶ where the *S* parameter defines a deviation from no interaction as is defined as:

$$S = \left(\frac{OD_{AB}}{OD_0} \right) \left(\frac{OD_{PNA}}{OD_0} \right) - \left(\frac{OD_{AB,PNA}}{OD_0} \right) \quad (\text{Equation 1})$$

Where OD_{AB} is the OD at 24 hours in only antibiotic, OD_0 is the OD at 24 hours without treatment, OD_{PNA} is the OD at 24 hours in only antisense-PNA at 10 µM, and $OD_{AB, PNA}$ is the OD at 24 hours in a combination of antibiotic and antisense-PNA. $S > 0$ is a deviation towards synergy and $S < 0$ is a deviation towards antagonism. *S* value significance was determined using a two-way ANOVA, setting a threshold p-value of 0.05 for the first-order interaction term.

HeLa Cell Culture: HeLa cells were stored as freezer stocks in 10% dimethyl sulfoxide (DMSO, Sigma) plus full media: Dulbecco’s Modified Eagle Medium (DMEM, Fisher Scientific), 10% Fetal Bovine Serum (FBS, Advanced, Atlanta Biologics), and 50 units/mL Penicillin-Streptomycin (P/S; Fisher Scientific). For biological replicates a single freezer stock, passage two, was split into three different culture flasks and each flask continuously passaged as individual biological replicates in full media. Cells were cultured at 37°C, 5% CO₂, and controlled humidity. Cells were passaged at 80% confluency with 0.25% trypsin (HyClone). For infection experiments, HeLa cells were seeded in 96 well

tissue culture treated plates (Fisher Scientific) at 45,000 cells/mL respectively in 100 μ L per well 24 hours prior to infection.

Salmonella infection of HeLa cells and PNA treatment: For a single infection (Fig. 4A-C), SL1344 cultures were inoculated from a single colony on solid media in to 1 mL of LB media with 30 μ g/mL streptomycin and grown for 16 hours at 37°C with shaking. Cultures were diluted 1:10 and regrown in LB containing streptomycin for three hours prior to infection. Bacteria were washed thrice with PBS, optical density at 600 nm measured, and diluted to a multiplicity of infection (MOI) of 10 in Dulbecco PBS (DPBS). MOI is calculated based on an established optical density and colony forming unit (CFU) calibration, and the number of mammalian cells per well at the time of infection approximated based on their 24-hour doubling time. Mammalian cells were washed thrice with Dulbecco's Phosphate-Buffered Saline (DPBS, Fisher Scientific) prior to addition of DPBS containing bacteria for a 45 minute infection at HeLa growth conditions. After infection media was replaced with HeLa full growth media containing 100 μ g/mL gentamicin instead of P/S to remove any extracellular bacteria and incubated for 75 minutes before replacement with full cell culture media containing 10 μ g/mL gentamicin instead of P/S and respective treatment and incubated for 18 hours.

Following 18 h treatment, wells for CFU analysis were washed thrice with 300 μ L DPBS and lysed with 30 μ L of 0.1% Triton X-100 for 15 minutes at room temperature. After 15 min, 270 μ L of PBS was added to each well then serially diluted and plated on sold LB media supplemented with 40 μ g/mL streptomycin. Plates were incubated for 16 hours at 37°C and CFU per milliliter determined. Wells for staining and imaging were fixed with 4% methanol-free paraformaldehyde at room temperature for 20 minutes. Staining for nuclei was performed using 100 μ L per well of 2.5 μ g/mL DAPI (Santa Cruz Biotechnology) for 5 minutes at room temperature then washed thrice with DPBS before staining with 100 μ L of 0.165 μ M Alexa Fluor 647 Phalloidin (Thermo Fisher) supplemented with 0.25% Triton X-100 for 20 minutes at room temperature. Cells were rinsed with DPBS and stored in 65% glycerol at 4°C. Images were acquired using an EVOS FL microscope and analyzed using ImageJ.

Double infection of HeLa cells and PNA treatment: For the double infection of HeLa cells with Target STm (SL1344-mCherry) and Delivery STm (SL1344-Holin) (Fig. 4D-F), single colonies were picked on solid media and grown overnight in 1 mL of LB broth supplemented with 30 µg/mL streptomycin and 100 µg/mL ampicillin. Overnight cultures were diluted 1:10 and regrown for 3 hours. After regrowth the cultures were washed thrice with PBS and diluted to a concentration of 9×10^6 CFU/mL (MOI of 10). The SL1344-Holin infection stock was split into no treatment and treatment; 10 µM of recA was added to the treatment condition and an equal volume of PBS was added to the no treatment. Both conditions were incubated for 45 minutes at 37°C mimicking the conditions used in the single infection experiment for the PNA to enter the *Salmonella*. After incubation all infection stocks (Target STm, Delivery STm with no treatment, and Delivery STm with treatment) were washed thrice with DPBS to remove any extracellular PNA. Each Delivery-STm and Target STm stock was combined at a 4:1 ratio to create the treatment and no treatment infection solutions and 50 µL was to infect the HeLa.

To ensure that the incubation ratio remained the same and PNA waste was minimized the DPBS washes were done with volumes under 1 mL resulting in variability of the actual MOI infected of each infection stock. To account for this variability each infection stock was serially diluted, plated, grown overnight, and CFUs counted to determine the exact number of bacteria that was used to infect for each condition. This extracellular CFU causing infection was measured for both Delivery STm and Target STm using fluorescence and is referred to as $CFU_{Delivery\ STm}^{Infected\ With}$ and $CFU_{Target\ STm}^{Infected\ With}$ respectively. For CFU counting the separate bacterial populations were separated by counting the Target STm as those colonies that fluoresced when excited by light at 587 nm in a light box and viewed through a 610 nm emission filter, and the Delivery STm as colonies showing lack of fluorescence at those wavelengths. At 18 h post-infection wells for CFU analysis were washed thrice with 300 µL PBS and lysed with 30 µL of 0.1% Triton X-100 for 15 minutes at room temperature. After 15 min, 270 µL of PBS was added to each well then serially diluted and plated on sold LB media supplemented with 40 µg/mL streptomycin. Plates were incubated for 16 hours at 37°C and CFU per milliliter determined. The intracellular CFU post lysis was measured for both SL1344-Holin and Target STm using fluorescence and

is referred to as $CFU_{Delivery\ STm}^{Lysed}$ and $CFU_{Target\ STm}^{Lysed}$ respectively. To account for variability of MOI we normalized the CFU of SL1344-Holin and Target STm cells using the ratio $\left(\frac{CFU_{Target\ STm}^{Lysed}}{CFU_{Target\ STm}^{Infected\ With}}\right)$ and $\left(\frac{CFU_{Delivery\ STm}^{Lysed}}{CFU_{Delivery\ STm}^{Infected\ With}}\right)$ respectively.

Effect of PNA after 45 min of incubation during HeLa infection: SL1344 were cultured as described above and split 1:10 and regrown for 3 hours. Samples were rinsed with PBS and diluted to a concentration equivalent to an MOI of 10 for a 24 hour grown culture of HeLa cells in 100 μ L. PNA (100 μ M) was added at 5 μ L to 45 μ L of bacteria and incubated for 45 minutes at culturing conditions. Samples (10 μ L) were taken at t=0 (before PNA addition) and t=45 min (after PNA treatment), and serially diluted, plated, and grown for 16 hours at 37°C and CFU counted.

Error and Significance Analysis: Error bars represent one standard deviation from the mean of biological replicates. In all cases, significance designated with an asterisk (*) is defined as $p < 0.05$ using a Student's t test.

REFERENCES

1. United States Center for Disease Control. *Antibiotic Resistance Threats*. (2013).
2. Tacconelli, E. & Magrini, N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. (2017).
3. O'Neill, J. Antimicrobial Resistance : Tackling a crisis for the health and wealth of nations. *Rev. Antimicrob. Resist.* (2016).
4. Levy, S. B. & Bonnie, M. Antibacterial resistance worldwide: Causes, challenges and responses. *Nature Medicine* (2004) doi:10.1038/nm1145.
5. WHO, W. H. O. & World Health Organization. *Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Who/Emp/Iau/2017.12* (2017).
6. Luepke, K. H. *et al.* Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. *Pharmacotherapy* (2017) doi:10.1002/phar.1868.
7. Trusts, P. C. Antibiotics Currently in Global Clinical Development. *Pew Charitable Trusts, Philadelphia, PA* https://www.pewtrusts.org/-/media/assets/2019/08/arp_antibiotics_currently_in_global_clinical_development_data_table_v2.pdf (2019).
8. Lázár, V. *et al.* Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. *Nat. Commun.* (2014) doi:10.1038/ncomms5352.
9. Gerber, J. S. *et al.* Association of broad- vs narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections. *JAMA - J. Am. Med. Assoc.* (2017) doi:10.1001/jama.2017.18715.
10. Yates, C. M., Shaw, D. J., Roe, A. J., Woolhouse, M. E. J. & Amyes, S. G. B. Enhancement of bacterial competitive fitness by apramycin resistance plasmids

- 1 from non-pathogenic Escherichia coli. *Biol. Lett.* (2006)
- 2 doi:10.1098/rsbl.2006.0478.
- 3 11. Hoban, D. J. Antibiotics and collateral damage. *Clin. Cornerstone* (2004)
- 4 doi:10.1016/S1098-3597(03)90025-1.
- 5 12. De Man, P., Verhoeven, B. A. N., Verbrugh, H. A., Vos, M. C. & Van Den Anker,
- 6 J. N. An antibiotic policy to prevent emergence of resistant bacilli. *Lancet* (2000)
- 7 doi:10.1016/S0140-6736(00)90015-1.
- 8 13. Hegarty, J. P. & Stewart, D. B. Advances in therapeutic bacterial antisense
- 9 biotechnology. *Applied Microbiology and Biotechnology* (2018)
- 10 doi:10.1007/s00253-017-8671-0.
- 11 14. Sully, E. K. & Geller, B. L. Antisense antimicrobial therapeutics. *Current Opinion*
- 12 *in Microbiology* (2016) doi:10.1016/j.mib.2016.05.017.
- 13 15. Giesen, U. *et al.* A formula for thermal stability (T(m)) prediction of PNA/DNA
- 14 duplexes. *Nucleic Acids Res.* **26**, 5004–5006 (1998).
- 15 16. Demidov, V. V. *et al.* Stability of peptide nucleic acids in human serum and
- 16 cellular extracts. *Biochem. Pharmacol.* (1994) doi:10.1016/0006-2952(94)90171-
- 17 6.
- 18 17. Nielsen, P. E., Egholm, M., Berg, R. H. & Buchardt, O. Sequence-selective
- 19 recognition of DNA by strand displacement with a thymine-substituted polyamide.
- 20 *Science* (80-.). (1991) doi:10.1126/science.1962210.
- 21 18. Choi, J.-J., Jang, M., Kim, J. & Park, H. Highly sensitive PNA array platform
- 22 technology for single nucleotide mismatch discrimination. *J. Microbiol. Biotechnol.*
- 23 **20**, 287–93 (2010).
- 24 19. Good, L., Awasthi, S. K., Dryselius, R., Larsson, O. & Nielsen, P. E. Bactericidal
- 25 antisense effects of peptide - PNA conjugates. *Nat. Biotechnol.* (2001)
- 26 doi:10.1038/86753.
- 27 20. Mondhe, M., Chessher, A., Goh, S., Good, L. & Stach, J. E. M. Species-selective

- 1 killing of bacteria by antimicrobial peptide-PNAs. *PLoS One* **9**, (2014).
- 2 21. Good, L. & Nielsen, P. E. Inhibition of translation and bacterial growth by peptide
3 nucleic acid targeted to ribosomal RNA. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 2073–
4 2076 (1998).
- 5 22. Soofi, M. A. & Seleem, M. N. Targeting essential genes in *Salmonella enterica*
6 serovar typhimurium with antisense peptide nucleic acid. *Antimicrob. Agents*
7 *Chemother.* (2012) doi:10.1128/AAC.01437-12.
- 8 23. Kurupati, P., Tan, K. S. W., Kumarasinghe, G. & Poh, C. L. Inhibition of gene
9 expression and growth by antisense peptide nucleic acids in a multiresistant beta-
10 lactamase-producing *Klebsiella pneumoniae* strain. *Antimicrob. Agents*
11 *Chemother.* **51**, 805–11 (2007).
- 12 24. Otsuka, T. *et al.* Antimicrobial activity of antisense peptide-peptide nucleic acid
13 conjugates against non-typeable *Haemophilus influenzae* in planktonic and biofilm
14 forms. *J. Antimicrob. Chemother.* (2017) doi:10.1093/jac/dkw384.
- 15 25. Bai, H. *et al.* Antisense inhibition of gene expression and growth in gram-negative
16 bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted
17 to rpoD gene. *Biomaterials* (2012) doi:10.1016/j.biomaterials.2011.09.075.
- 18 26. Courtney, C. M. & Chatterjee, A. Sequence-Specific Peptide Nucleic Acid-Based
19 Antisense Inhibitors of TEM-1 β -Lactamase and Mechanism of Adaptive
20 Resistance. *ACS Infect. Dis.* **1**, 253–263 (2015).
- 21 27. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat.*
22 *Methods* (2012) doi:10.1038/nmeth.1923.
- 23 28. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics*
24 **25**, 2078–2079 (2009).
- 25 29. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing
26 genomic features. *Bioinformatics* **26**, 841–2 (2010).
- 27 30. Szklarczyk, D. *et al.* STRING v10: Protein-protein interaction networks, integrated

- over the tree of life. *Nucleic Acids Res.* (2015) doi:10.1093/nar/gku1003.
31. Schoeffler, A. J., May, A. P. & Berger, J. M. A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function. *Nucleic Acids Res.* **38**, 7830–44 (2010).
32. Andersson, D. I., Bohman, K., Isaksson, L. A. & Kurland, C. G. Translation rates and misreading characteristics of rpsD mutants in Escherichia coli. *MGG Mol. Gen. Genet.* **187**, 467–472 (1982).
33. Phillips, G. J. & Silhavy, T. J. The E. coli ffh gene is necessary for viability and efficient protein export. *Nature* (1992) doi:10.1038/359744a0.
34. Little, J. W. & Mount, D. W. The SOS regulatory system of Escherichia coli. *Cell* (1982) doi:10.1016/0092-8674(82)90085-X.
35. Ma, D. *et al.* Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli. *Mol. Microbiol.* **16**, 45–55 (1995).
36. Bognar, A. L., Osborne, C., Shane, B., Singer, S. C. & Ferone, R. Folylpoly-γ-glutamate synthetase-dihydrofolate synthetase. *J. Biol. Chem.* **260**, 5625–5630 (1985).
37. Brombacher, E., Dorel, C., Zehnder, A. J. B. & Landini, P. The curli biosynthesis regulator CsgD co-ordinates the expression of both positive and negative determinants for biofilm formation in Escherichia coli. *Microbiology* **149**, 2847–57 (2003).
38. Salmon, K. *et al.* Global gene expression profiling in Escherichia coli K12. The effects of oxygen availability and FNR. *J. Biol. Chem.* **278**, 29837–55 (2003).
39. Fernández De Henestrosa, A. R. *et al.* Identification of additional genes belonging to the LexA regulon in Escherichia coli. *Mol. Microbiol.* **35**, 1560–1572 (2000).
40. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. *CLSI Suppl. M100* (2017).
41. Hatamoto, M., Ohashi, A. & Imachi, H. Peptide nucleic acids (PNAs) antisense

- effect to bacterial growth and their application potentiality in biotechnology.
Applied Microbiology and Biotechnology (2010) doi:10.1007/s00253-009-2387-8.
42. Koppelhus, U. & Nielsen, P. E. Cellular delivery of peptide nucleic acid (PNA).
Adv. Drug Deliv. Rev. **55**, 267–280 (2003).
43. Deere, J., Iversen, P. & Geller, B. L. Antisense phosphorodiamidate morpholino
oligomer length and target position effects on gene-specific inhibition in
Escherichia coli. *Antimicrob. Agents Chemother.* (2005)
doi:10.1128/AAC.49.1.249-255.2005.
44. BLISS, C. I. THE TOXICITY OF POISONS APPLIED JOINTLY. *Ann. Appl. Biol.*
(1939) doi:10.1111/j.1744-7348.1939.tb06990.x.
45. Dryselius, R., Nekhotiaeva, N. & Good, L. Antimicrobial synergy between mRNA-
and protein-level inhibitors. *J. Antimicrob. Chemother.* (2005)
doi:10.1093/jac/dki173.
46. Castillo, J. I., Równicki, M., Wojciechowska, M. & Trylska, J. Antimicrobial
synergy between mRNA targeted peptide nucleic acid and antibiotics in *E. coli*.
Bioorganic Med. Chem. Lett. (2018) doi:10.1016/j.bmcl.2018.07.037.
47. Gupta, A., Bahal, R., Gupta, M., Glazer, P. M. & Saltzman, W. M. Nanotechnology
for delivery of peptide nucleic acids (PNAs). *J. Control. Release* **240**, 302–311
(2016).
48. Goltermann, L., Yavari, N., Zhang, M., Ghosal, A. & Nielsen, P. E. PNA length
restriction of antibacterial activity of peptide-PNA conjugates in *Escherichia coli*
through effects of the inner membrane. *Front. Microbiol.* **10**, (2019).
49. Kubori, T. *et al.* Supramolecular structure of the salmonella typhimurium type III
protein secretion system. *Science* (80-.). (1998)
doi:10.1126/science.280.5363.602.
50. Deng, W. *et al.* Assembly, structure, function and regulation of type III secretion
systems. *Nat. Rev. Microbiol.* **15**, 323–337 (2017).

51. Vazquez-Terres, A. *et al.* Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. *Nature* (1999) doi:10.1038/44593.
52. Young, R. Phage lysis: three steps, three choices, one outcome. *J. Microbiol.* **52**, 243–58 (2014).
53. Bordoy, A. E., O'Connor, N. J. & Chatterjee, A. Construction of Two-Input Logic Gates Using Transcriptional Interference. *ACS Synth. Biol.* (2019) doi:10.1021/acssynbio.9b00321.
54. Bérdy, J. Thoughts and facts about antibiotics: Where we are now and where we are heading. *Journal of Antibiotics* (2012) doi:10.1038/ja.2012.27.
55. Baba, T. *et al.* Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: The Keio collection. *Mol. Syst. Biol.* (2006) doi:10.1038/msb4100050.
56. Gildea, B. D. & Coull, J. M. Methods for Modulating the Solubility of Synthetic Polymers. (2004).
57. Keseler, I. M. *et al.* The EcoCyc database: Reflecting new knowledge about Escherichia coli K-12. *Nucleic Acids Res.* (2017) doi:10.1093/nar/gkw1003.
58. Gama-Castro, S. *et al.* RegulonDB version 9.0: High-level integration of gene regulation, coexpression, motif clustering and beyond. *Nucleic Acids Res.* (2016) doi:10.1093/nar/gkv1156.
59. Bolger, A. M. *et al.* Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
60. Zerbino, D. R. & Birney, E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome Res.* **18**, 821–829 (2008).
61. Bankevich, A. *et al.* SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. *J. Comput. Biol.* (2012) doi:10.1089/cmb.2012.0021.
62. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**,

2068–2069 (2014).

63. Rowe, W. *et al.* Search engine for antimicrobial resistance: A cloud compatible pipeline and web interface for rapidly detecting antimicrobial resistance genes directly from sequence data. *PLoS One* (2015) doi:10.1371/journal.pone.0133492.

64. Gupta, S. K. *et al.* ARG-annot, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob. Agents Chemother.* **58**, 212–220 (2014).

65. Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief. Bioinform.* **14**, 178–92 (2013).

66. Hegreness, M., Shores, N., Damian, D., Hartl, D. & Kishony, R. Accelerated evolution of resistance in multidrug environments. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 13977–13981 (2008).

Figure 1. Facile Accelerated Specific Therapeutic (FAST) platform from design to delivery of PNA to treat MDR bacteria in less than one week. The FAST pipeline is capable of producing effective therapies against MDR bacteria by combining design, synthesis, testing, and delivery modules. Design (top left corner): The corresponding reference genome of target pathogen(s) is inputted into the PNA Finder bioinformatics toolbox which generates a list of PNA sequences in less than 10 minutes. Build (top right corner): Promising PNA candidates are synthesized using high-throughput, automated solid-phase synthesis chemistry. Purification of the PNA product is done using HPLC and validation is performed through LC-MS. The entire process is completed in less than 4 days. Test (bottom right corner): The purified and verified PNA is tested on clinical isolates within 1 day to evaluate therapeutic potential for monotherapy or combination (with antibiotic (AB)) treatments. Delivery (bottom left corner) Top PNA candidates are delivered to infected mammalian cells by repurposing the bacterial Type III Secretion System (T3SS) mediated delivery system to clear a secondary (red bacteria) intracellular infection.

Figure 2. Bioinformatics design of PNAs used to synthesis, purification, and monotherapy testing. (A) Bioinformatic toolbox predicts PNAs that can target essential and non-essential genes in one or more Enterobacteriaceae including *E. coli*, *K. pneumoniae* (KPN), and *S. enterica* (STm). Here, PNAs targeting *E. coli*'s genome are identified and screened for internal off-targets. Candidates without off-targets are narrowed to those with homology among KPN and STm. Of the final 71 essential gene candidates and 243 non-essential gene candidates that met the thermodynamic requirements for experimental conditions, five and four PNAs targeting essential and non-essential gene respectively were randomly chosen for assessment. Most of the PNAs have homology to all three Enterobacteriaceae in this study, except α -folC, α -csgD, and α -fmr

which are designed to be specific to *E. coli*, and α -recA which is specific to *E. coli* and STm. PNAs α -folC, α -ffh, α -lexA, α -acrA, α -recA, α -csgD, and α -fnr target novel pathways of metabolism, signal recognition, stress response, transport, stress response, biofilm formation, and metabolism respectively. PNAs α -gyrB and α -rpsD target novel genes in traditional antibiotic pathways. **(B)** Following PNA solid-phase synthesis, the product is purified using HPLC (representative chromatogram shown), verified by LCMS (representative spectra shown), and tested against a lab strain of *E. coli* (MG1655, growth curves for α -lexA and α -rpsD shown). **(C)** Antibiotic resistance characterization of clinical isolates of CRE *E. coli*, MDR *E. coli*, ESBL KPN, NDM-1 KPN, and MDR *S. Typhimurium*. (Left) Antibiotic resistance characterization of clinical isolates used in this study. Letters “R”, “S”, and “I” indicate drug-resistance, sensitivity, and intermediate resistance respectively. Sensitive, Intermediate, and Resistant breakpoints are provided in Table S1. Nine antibiotics of varied mechanisms and classes were tested including penicillins (ampicillin, AMP), cephalosporins (ceftriaxone, FRX), carbapenems (meropenem, MER), aminoglycosides (gentamicin, GEN and kanamycin, KAN), tetracyclines (tetracycline, TET), fluoroquinolones (ciprofloxacin, CIP), quinolones (nalidixic acid, NXA), and phenicols. **(D)** Clinical isolate monotherapy testing is done by monitoring growth at OD_{600 nm} over 16 hours. Shown here are representative growth curves from four of the clinical isolates: NDM-1 KPN and a PNA control, α -nonsense, MDR *E. coli* and α -ffh, CRE *E. coli* and α -rpsD, and MDR STm and α -acrA. **(E-F)** Normalized growth (ratio of optical density of treatment to no treatment at 16 hours) of clinical isolates in the presence of treatment with 10 μ M of the indicated PNA. PNAs targeting essential and non-essential genes and showing at least 50% growth inhibition are shown in panels **E** and **F** respectively with significance (represented by an asterisk, p-val < 0.05) determined relative to control nonsense PNA and no treatment respectively. All data shown are the average of 3 biological replicates with standard deviation shown as error bars.

Figure 3. FAST platform generates PNAs that can potentiate activity of traditional small-molecule antibiotics. (A) Using the STRING database of protein network interactions (data shown in Supplementary Figure S12), we found a positive correlation, Pearson's $r = 0.4793$ and $p < 0.001$, between growth inhibition of PNA homologous with target bacteria and average node degree, the number of interactions of protein has in the average network. (B-M) Subsequent growth curves and bar plots show bacteria without treatment, or treatment with PNA alone (10 μ M), or antibiotic alone, or PNA and antibiotic combined. Antibiotic concentrations were (from top to bottom) 2 μ g/mL tetracycline (TET), 4 μ g/mL gentamicin (GEN), and 8 μ g/mL chloramphenicol (CHL). (B,F,J) The first column shows representative growth curves over 24 hours of each treatment. Panels B-E and F-G show treatment of CRE *E. coli* with PNAs targeting essential and non-essential genes respectively. Panels J-M shows treatment of ESBL KPN with PNAs targeting essential genes. All bar plots are the average OD (600 nm) of each treatment at 24 hours normalized to no treatment at 24 hours. S values above the bar plots were obtained using the Bliss Independence model and indicate synergistic interaction between PNA and antibiotic, an Asterisk indicates significance at $\alpha = 0.05$. (N) Plotting the S values representing synergy against the target protein's average node degree shows a negative correlation (Pearson's $r = -0.3017$, $p = 0.0314$). All data shown are the average of 3 biological replicates with standard deviation shown as error bars.

Figure 4. Repurposing the bacterial Type III secretion system (T3SS) for PNA delivery and release to clear intracellular infections of mammalian cells. (A) Schematic showing the experimental setup for comparing PNA delivery into HeLa cells for treating an intracellular

infection of *Salmonella enterica* serovar Typhimurium, strain SL1344 expressing GFP (STm-GFP), using either the bacterial T3SS inherent to STm-GFP (Bottom, T3SS-PNA) or CPP facilitated uptake (Top, Naked-PNA). All intracellular infection treatment experiments follow the general protocol of 45-minute infection of HeLa cells 24 hours after seeding, 75-minute gentamicin treatment to remove extracellular bacteria, and 18-hour incubation with treatment in media containing gentamicin to ensure an only intracellular infection model. For comparing T3SS delivered PNA to Naked-PNA infection was done using STm-GFP at an MOI of 10. For the T3SS-PNA condition 10 μ M of PNA was added during this 45-minute infection stage; during this time the PNA is allowed to enter the *Salmonella* and subsequently be transported into the HeLa cell as it infects via its T3SS. For the Naked-PNA condition 10 μ M of PNA is added to the gentamicin containing media that the HeLa cells are incubated in for 18 hours. Post 18 hours of treatment HeLa cells are fixed for imaging or lysed for Colony forming Unit (CFU) analysis. **(B)** Representative images of HeLa cells uninfected (top left), infected and without treatment (bottom left), infected and treated with Naked-PNA (top right), and infected and treated with T3SS-PNA (bottom right). HeLa cells are stained with the nuclear stain DAPI (blue), the membrane stain Phalloidin (pink), and green pixels represent intracellular STm-GFP (green). Images show an evident decrease in STm-GFP during T3SS- α -rpsD or T3SS- α -lexA treatment compared to no treatment or with Naked-PNA treatment. **(C)** Percent infection (CFU/mL of treatment normalized to No Treatment) in the presence or absence of treatment. Significant reduction in STm in HeLa cells when PNA is delivered using T3SS. Naked-PNA treatment does not produce significant therapeutic effect. **(D)** Schematic showing the experimental setup comparing the delivery and release approach to no treatment of an intracellular infection of HeLa cells. The same procedure was followed as in part A with few modifications. Pretreatment of the Delivery STm (STm-GFP modified with Holin release switch) is done by incubating in either 10 μ M of PNA (Bottom, T3SS/Holin-PNA) or PBS (Top, No Treatment) for 45 minutes to allow for PNA uptake. Then HeLa cells are infected with a 4:1 ratio of Delivery STm (green) to Target STm (red), making the total MOI 10. After removing extracellular bacteria, the infected HeLa cells are incubated for 18 hours; during this time the Delivery STm releases the PNA to treat the Target STm strain. After 18-hours of incubation the HeLa cells are lysed to determine the number of intracellular colony forming units. **(E)** CFU ratio of normalized Target STm to Normalized Delivery STm (see methods section for normalization) shows significant reduction compared to no treatment. Triangles represent individual biological replicates of HeLa cells. **(F)** Percent infection of Target STm (Target STm CFU normalized to no treatment) when using a non-T3SS bacteria (*E. coli* MG1655) as the Delivery strain shows no reduction ($p>0.05$).